DOI : 10.1055/s-00000059

Pneumologie

Issue S 01 · Volume 69 · March 2015 DOI: 10.1055/s-005-28563


56. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.
Berlin, 18.–21. 3. 2015

Kongresspräsident: Prof. Dr. med. Torsten T. Bauer, Berlin
Abstracts (HTML) List of Authors
P28
Geßner, C; Schürmann, W; Förster, K; Sieder, C; Hiltl, S; Buhl, R; Korn, S: QVA149 einmal täglich verbessert Lungenfunktion und Atemnot im Vergleich zur freien Kombination aus Tiotropium plus Formoterol: die QUANTIFY-Studie
P55
Kirsten, AM; Richards, A; Tanase, AM; Weihua, C; Hosoe, M; Hederer, B: Wirksamkeit und Sicherheit von Indacaterol/Mometason (1x/Tag) verglichen mit Salmeterol/Fluticason (2x/Tag) bei Patienten mit mäßiger bis sehr schwerer COPD
P67
Watz, H; Calverley, P; Chanez, P; Dahl, R; Decramer, M; Disse, B; Finnigan, H; Kirsten, AM; Rodriguez-Roisin, R; Tetzlaff, K; Towse, L; Wouters, E; Magnussen, H: The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study
P75
Magnussen, H; Chanez, P; Dahl, R; Decramer, M; Disse, B; Finnigan, H; Kirsten, AM; Rodriguez-Roisin, R; Tetzlaff, K; Towse, L; Watz, H; Wouters, E; Calverley, P: The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study
P77
Kirsten, AM; Maltais, F; Iturri, JBG; Singh, D; Hamilton, A; Tetzlaff, K; Zhao, Y; Casaburi, R: Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD
P126
Hohlfeld, J; Furtwängler, A; Könen-Bergmann, M; Wallenstein, G; Walter, B; Bateman, ED: Evaluating cardiac safety of tiotropium in patients with COPD: Combined analysis of Holter-ECG data from four trials
P127
Hohlfeld, J; Calverley, P; Könen-Bergmann, M; Metzdorf, N; Bell, S: Tiotropium Respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg doses
P169
Jones, PW; Korn, S; Scanlon, PD; Singh, D; Mergel, V; Molins, E; Leselbaum, A: Effects of aclidinium bromide/formoterol fumarate fixed-dose combination on health status in COPD
P171
Buhl, R; Derom, E; Ferguson, G; Maltais, F; Pizzichini, E; Reid, J; Watz, H; Groenke, L; Hamilton, A; Tetzlaff, K; Korducki, L; Huisman, H; Waitere-Wijker, S; Bateman, E: Once-daily tiotropium and olodaterol fixed-dose combination via the Respimat improves outcomes vs mono-components in COPD in two 1-year studies
P177
Buhl, R; Abrahams, R; Bjermer, L; Derom, E; Fležar, M; Hébert, J; Veale, A; Groenke, L; Hamilton, A; Tetzlaff, K; Korducki, L; Huisman, H; Waitere-Wijker, S; McGarvey, L: Safety of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat in chronic obstructive pulmonary disease in two 1-year studies
P191
Wild, C; Brutsche, MH: Günstiger Therapieeffekt einer freien dualen Bronchodilatation auf die statische Hyperinflation bei COPD – SYNERGY-Zwischenbericht
P231
Beier, J; Plate, T; Prechtl, A: Symptom severity and quality of life in COPD patients treated with aclidinium bromide: results of a non-interventional study
P287
Jones, PW; D'Urzo, A; Rennard, S; Molins, E; Mergel, V; Leselbaum, A: Effect of aclidinium/formoterol fixed-dose combinations on respiratory symptoms in patients with COPD